HomeCompareAGS vs PFE

AGS vs PFE: Dividend Comparison 2026

AGS yields 16.01% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AGS wins by $5.9K in total portfolio value
10 years
AGS
AGS
● Live price
16.01%
Share price
$12.49
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.0K
Annual income
$4,290.66
Full AGS calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — AGS vs PFE

📍 AGS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAGSPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AGS + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AGS pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AGS
Annual income on $10K today (after 15% tax)
$1,361.09/yr
After 10yr DRIP, annual income (after tax)
$3,647.06/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, PFE beats the other by $19,481.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AGS + PFE for your $10,000?

AGS: 50%PFE: 50%
100% PFE50/50100% AGS
Portfolio after 10yr
$54.0K
Annual income
$15,750.60/yr
Blended yield
29.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

AGS
Analyst Ratings
5
Buy
5
Hold
2
Sell
Consensus: Buy
Price Target
$13.17
+5.4% upside vs current
Range: $11.00 — $16.00
Altman Z
1.0
Piotroski
8/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AGS buys
0
PFE buys
0
No recent congressional trades found for AGS or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAGSPFE
Forward yield16.01%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$57.0K$51.1K
Annual income after 10y$4,290.66$27,210.54
Total dividends collected$28.7K$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold
Analyst price target$13.17$27.50

Year-by-year: AGS vs PFE ($10,000, DRIP)

YearAGS PortfolioAGS Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$12,301$1,601.28$9,161$701.38+$3.1KAGS
2$15,003$1,840.92$8,610$859.79+$6.4KAGS
3$18,152$2,098.39$8,366$1,081.25+$9.8KAGS
4$21,795$2,372.68$8,483$1,405.66+$13.3KAGS
5$25,983$2,662.52$9,084$1,907.24+$16.9KAGS
6$30,769$2,966.50$10,418$2,732.78+$20.4KAGS
7$36,206$3,283.03$13,007$4,193.56+$23.2KAGS
8$42,350$3,610.41$18,010$7,005.87+$24.3KAGS
9$49,262$3,946.89$28,216$12,979.89+$21.0KAGS
10$57,001$4,290.66$51,081$27,210.54+$5.9KAGS

AGS vs PFE: Complete Analysis 2026

AGSStock

PlayAGS, Inc. designs and supplies gaming products and services for the gaming industry in the United States and internationally. It operates through three segments: Electronic Gaming Machines (EGM), Table Products, and Interactive Games (Interactive). The EGM segment offers various video slot titles for the marketplace; and EGM cabinets, including the Orion Starwall, Orion Curve Premium, Big Red, Orion Portrait, Orion Slant, Orion Curve, Orion Upright, and ICON. This segment also provides conversion kits that allow existing game titles to be converted to other game titles offered within that operating platform. It serves Class II Native American and Mexico, as well as Class III Native American, commercial, and charitable jurisdictions. The Table Products segment offers table products, including live felt table games, side bet offerings, progressives, card shufflers, signage, and other ancillary table game equipment, as well as table technology related to blackjack, poker, baccarat, craps, and roulette. This segment also provides Dex S, a single deck card shuffler for poker tables. Its brands include In Bet, Buster Blackjack, Double Draw Poker, and Criss Cross Poker. The Interactive segment offers a platform for business-to-business content aggregation used by real-money gaming and sports-betting partners; and business-to-consumer social casino games through its mobile app, Lucky Play Casino. The company was formerly known as AP Gaming Holdco, Inc. and changed its name to PlayAGS, Inc. in December 2017. PlayAGS, Inc. was incorporated in 2005 and is headquartered in Las Vegas, Nevada.

Full AGS Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this AGS vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AGS vs SCHDAGS vs JEPIAGS vs OAGS vs KOAGS vs MAINAGS vs JNJAGS vs MRKAGS vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.